发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Bimekizumab for the treatment of psoriasis. 用于治疗银屑病的 Bimekizumab。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-20 DOI: 10.2217/imt-2023-0240
Molly Thapar, Milan Patel, Kenneth Gordon
{"title":"Bimekizumab for the treatment of psoriasis.","authors":"Molly Thapar, Milan Patel, Kenneth Gordon","doi":"10.2217/imt-2023-0240","DOIUrl":"10.2217/imt-2023-0240","url":null,"abstract":"<p><p>Psoriasis is a chronic inflammatory skin condition characterized by Th17 T cell-mediated inflammation. An emerging treatment option for psoriasis is bimekizumab, a humanized monoclonal antibody targeting cytokines IL-17A and IL-17F. Phase I trials evaluating bimekizumab reported strong safety, tolerability, and clinical efficacy with most common treatment emergent adverse events being mild to moderate in nature. Phase II trials evaluated dosing intervals, revealing that higher dosages or more frequent administration of bimekizumab resulted in minimal increases in adverse events. Phase III trials and open label extension studies demonstrated a rapid, sustained clinical response when compared with placebo and active comparators. Bimekizumab shows strong efficacy in the treatment of psoriasis and has potential in the treatment of other Th17-mediated pathologies.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"431-446"},"PeriodicalIF":2.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma. 原发性肝肉瘤样癌中 PD-L1 强表达对治疗和预后的影响。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI: 10.2217/imt-2023-0243
Subathra Radhakrishnan, Catherine Ann Martin, Mukul Vij, Komalavalli Subbiah, Lexmi Priya Raju, Gowripriya Gowrishankar, Vidya Harini Veldore, Ilankumaran Kaliamoorthy, Ashwin Rammohan, Mohamed Rela
{"title":"Treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma.","authors":"Subathra Radhakrishnan, Catherine Ann Martin, Mukul Vij, Komalavalli Subbiah, Lexmi Priya Raju, Gowripriya Gowrishankar, Vidya Harini Veldore, Ilankumaran Kaliamoorthy, Ashwin Rammohan, Mohamed Rela","doi":"10.2217/imt-2023-0243","DOIUrl":"10.2217/imt-2023-0243","url":null,"abstract":"<p><p>Primary hepatic sarcomatoid carcinoma (HSC) is an extremely rare and aggressive subtype of primary liver cancer. HSC has uncertain pathogenesis and dismal prognosis with overall survival of only 8.3 months. The molecular alterations of HSC are also not well understood. In this study, the authors describe a patient who presented with a large liver mass. The patient underwent complete surgical resection and histological examination demonstrated HSC, infiltrating the stomach. PD-L1 was strongly positive in the tumor cells. The patient was started on anti-PD-L1 immunotherapy postsurgery and is doing well 15 months after surgical resection. Tumor whole exome sequencing revealed genetic alterations in <i>TP53</i>, <i>NF2</i> and <i>MAGEC3</i> genes, indicating their potential role in tumor development.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"371-379"},"PeriodicalIF":2.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer. 转移性非小细胞肺癌患者使用彭博拉珠单抗-铂-培美曲塞诱导治疗后培美曲塞维持治疗的疗效分层。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-03-15 DOI: 10.2217/imt-2023-0313
Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, Yunfei Wang, Melissa L Santorelli, Thomas Burke, Nathan A Pennell
{"title":"Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer.","authors":"Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, Yunfei Wang, Melissa L Santorelli, Thomas Burke, Nathan A Pennell","doi":"10.2217/imt-2023-0313","DOIUrl":"10.2217/imt-2023-0313","url":null,"abstract":"<p><p><b>Aim:</b> We assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab-platinum-pemetrexed (induction) in US community oncology settings. <b>Methods:</b> Patients initiating induction were retrospectively identified. Patients continuing pembrolizumab afterward underwent chart review. Clinical outcomes were described by maintenance pemetrexed exposure after inverse probability of treatment weighting (IPTW). <b>Results:</b> Median induction pembrolizumab and pemetrexed durations were 5.1 and 4.2 months. Among patients continuing pembrolizumab after induction, 64% received maintenance pemetrexed. Common discontinuation reasons for induction pemetrexed were completion of planned therapy (79%) and partial response (68%) and progressive disease (38%) and toxicity (29%) for maintenance pemetrexed. After IPTW, median overall survival and real-world progression-free survival were longer in patients continuing pembrolizumab with versus without maintenance pemetrexed (20.3 vs 12.0 months and 10.3 vs 5.8 months, respectively). <b>Conclusion:</b> Patient characteristics and planned treatment decisions affect maintenance pemetrexed utilization in the community oncology setting.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"453-464"},"PeriodicalIF":2.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140131350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune checkpoint inhibitors in follicular dendritic cell sarcoma. 免疫检查点抑制剂在滤泡树突状细胞肉瘤中的应用。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-04-01 Epub Date: 2024-02-16 DOI: 10.2217/imt-2023-0230
Tarek Assi, Axel Le Cesne
{"title":"Immune checkpoint inhibitors in follicular dendritic cell sarcoma.","authors":"Tarek Assi, Axel Le Cesne","doi":"10.2217/imt-2023-0230","DOIUrl":"10.2217/imt-2023-0230","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"341-344"},"PeriodicalIF":2.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serplulimab monotherapy in extensive-stage small-cell lung cancer with brain metastasis: a case report. Serplulimab 单药治疗广泛期小细胞肺癌伴脑转移：一份病例报告。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-27 DOI: 10.2217/imt-2023-0323
Xudong Xiang, Heng Li, Bao Lei, Benchao Chen, Gaofeng Li
{"title":"Serplulimab monotherapy in extensive-stage small-cell lung cancer with brain metastasis: a case report.","authors":"Xudong Xiang, Heng Li, Bao Lei, Benchao Chen, Gaofeng Li","doi":"10.2217/imt-2023-0323","DOIUrl":"https://doi.org/10.2217/imt-2023-0323","url":null,"abstract":"<p><p>Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with limited treatment options, especially for extensive-stage (ES) patients. We present a case of a 70-year-old male with ES-SCLC and asymptomatic brain metastasis who opted for immune monotherapy with serplulimab (an anti-PD-1 antibody). After four cycles, the patient achieved a confirmed partial response and a progression-free survival of over 1 year. Moreover, we observed a consistent decline in tumor biomarkers, and brain MRI indicated reduced metastatic activity. Remarkably, the patient tolerated the treatment well, with only mild diarrhea. This case highlights serplulimab's potential as a first-line treatment in select ES-SCLC patients, emphasizing the importance of further research on immunotherapy predictive biomarkers.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Certolizumab pegol in the treatment of axial spondyloarthritis. 赛妥珠单抗 pegol 用于治疗轴性脊柱关节炎。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-26 DOI: 10.2217/imt-2023-0225
Elizabeth Anderson, Secia Beier, Julianna Desmarais
{"title":"Certolizumab pegol in the treatment of axial spondyloarthritis.","authors":"Elizabeth Anderson, Secia Beier, Julianna Desmarais","doi":"10.2217/imt-2023-0225","DOIUrl":"https://doi.org/10.2217/imt-2023-0225","url":null,"abstract":"<p><p>Axial spondyloarthritis is a chronic, immune-mediated systemic inflammatory disease encompassing ankylosing spondylitis and nonradiographic axial spondyloarthritis. TNF inhibitors are the preferred second line therapy for patients with active axial spondyloarthritis. Certolizumab pegol is a TNF inhibitor approved for treatment of both. Three large phase III trials (RAPID-axSpA, C-axSpAnd and C-OPTIMISE) and one large phase IV trial (CIMAX) establish its clinical efficacy in treatment of active disease and maintenance of remission for both diseases. Real world evidence demonstrates clinical efficacy and benefits including reduced bone loss, reduced risk of uveitis, safety in pregnancy and lactation and index drug survival of 10 years. It is generally well tolerated, though can be associated with increased risk of serious infections.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review. 辛替利马引发的严重糜烂性出血性胃炎和幽门梗阻：病例报告和文献综述。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-26 DOI: 10.2217/imt-2023-0325
Wenfang Xiong, Zhenzhen Yang, Youxiang Chen
{"title":"Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review.","authors":"Wenfang Xiong, Zhenzhen Yang, Youxiang Chen","doi":"10.2217/imt-2023-0325","DOIUrl":"https://doi.org/10.2217/imt-2023-0325","url":null,"abstract":"<p><p>Immune checkpoint inhibitors could restore immune surveillance to attack tumor through targeting CTLA-4, PD-1 or PD-L1, and have achieved huge success. However, immune-related adverse events (irAEs) have been attracting attention as their application is expanding. Gastritis is relatively rare as a subtype of irAEs, particularly severe gastritis. Guidelines on its clinical management still remain undefined due to limited data. Sintilimab is a PD-1 inhibitor approved in China. Here we offer a case of sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction. Conventional proton pump inhibitors and mucosal protective agents did not take effect, so glucocorticoid was chosen. This severe gastritis was successfully cured finally. Our report describing its clinical performances, endoscopic characteristics and treatments, could assist clinicians to better know this rare irAE.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma. 使用屋尘螨提取物的过敏原免疫疗法对小儿支气管哮喘的疗效。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-26 DOI: 10.2217/imt-2024-0024
Masaaki Hamada, Keigo Saeki, Ichiro Tanaka
{"title":"Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma.","authors":"Masaaki Hamada, Keigo Saeki, Ichiro Tanaka","doi":"10.2217/imt-2024-0024","DOIUrl":"https://doi.org/10.2217/imt-2024-0024","url":null,"abstract":"<p><p><b>Aim:</b> We compared the effectiveness of rush subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) using standardized house dust mite (HDM) extract for pediatric bronchial asthma (BA). <b>Methods:</b> We followed the pediatric BA treatment score during 3 years of treatment. We assessed the median time to no longer requiring long-term control pharmacotherapy (LTCP) for BA (LTCP-free). We compared the outcomes after adjustment for confounding factors and propensity score matching. <b>Results:</b> Patients in the HDM SCIT group achieved the LTCP-free status significantly earlier than those in the HDM SLIT group after adjustment for confounding factors and propensity score matching. <b>Conclusion:</b> Patients treated for pediatric BA with rush HDM SCIT had earlier onset of therapeutic effects than those with HDM SLIT.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158. 彭博利珠单抗在中国微卫星不稳定性高/错配修复缺陷肿瘤患者中的应用KEYNOTE-158。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-20 DOI: 10.2217/imt-2023-0294
Jianming Xu, Yimin Mao, Nong Xu, Yuxian Bai, Dong Wang, Xiaojun Chen, Xianli Yin, Yanhong Deng, Jianwei Yang, Jieqing Zhang, Jie Tang, Yi Huang, Jiayi Li, Suxia Luo, Hong Zheng, Weidong Zhao, Miaomiao Xu, Nan Li, Yixiang Mao, Alexander Gozman, Xiaohua Wu
{"title":"Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158.","authors":"Jianming Xu, Yimin Mao, Nong Xu, Yuxian Bai, Dong Wang, Xiaojun Chen, Xianli Yin, Yanhong Deng, Jianwei Yang, Jieqing Zhang, Jie Tang, Yi Huang, Jiayi Li, Suxia Luo, Hong Zheng, Weidong Zhao, Miaomiao Xu, Nan Li, Yixiang Mao, Alexander Gozman, Xiaohua Wu","doi":"10.2217/imt-2023-0294","DOIUrl":"https://doi.org/10.2217/imt-2023-0294","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate pembrolizumab in patients of Chinese descent with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) tumors enrolled in KEYNOTE-158 (Cohort L). <b>Methods:</b> Patients with MSI-H/dMMR advanced tumors received pembrolizumab 200 mg IV Q3W. Primary end point was overall response rate (ORR). Secondary end points were duration of response (DOR), progression-free survival (PFS) and overall survival (OS). <b>Results:</b> 24 patients were enrolled (20 were evaluable for efficacy). With median follow-up of 12.4 months, the ORR was 70%. DOR, PFS and OS were all not reached. A total of 19 (79%) patients had a treatment-related adverse event (AE; grade ≥3 in 4 [17%]), and 8 (33%) had an immune-mediated AE (grade ≥3 in (4 [17%]). <b>Conclusion:</b> Pembrolizumab provided meaningful and durable responses with manageable safety. These results are consistent with those reported for the global trial.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BATF-mediated regulation of exhausted CD8+ T-cell responses and potential implications for chimeric antigen receptor-T therapy. BATF 介导的 CD8+ T 细胞衰竭反应调控以及对嵌合抗原受体-T 疗法的潜在影响。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-03-01 Epub Date: 2024-01-24 DOI: 10.2217/imt-2023-0170
Chao Sun, Dan Li, Zhengxin Wang
{"title":"<i>BATF</i>-mediated regulation of exhausted CD8<sup>+</sup> T-cell responses and potential implications for chimeric antigen receptor-T therapy.","authors":"Chao Sun, Dan Li, Zhengxin Wang","doi":"10.2217/imt-2023-0170","DOIUrl":"10.2217/imt-2023-0170","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T-cell therapy for malignant tumors has reached a crucial stage, with recent studies underscoring the role of T-cell exhaustion in determining the efficacy of CAR-T therapy. This trailblazing discovery has opened new avenues to augment the potency of CAR-T therapy. Basic leucine zipper ATF-like transcription factor (<i>BATF</i>) is indispensable in alleviating T-cell exhaustion and is pivotal in the early stages of CD8<sup>+</sup> T-cell differentiation. In cooperation with other transcription factors, it plays a key role in the differentiation and maturation processes of exhausted T cells. A deeper comprehension of <i>BATF</i>'s mechanisms in T-cell biology may yield novel insights into amplifying the efficacy of CAR-T therapy.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"331-340"},"PeriodicalIF":2.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139540991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信